Tamara Maes
unknownFemale0.0Global Dominance: 0.00%
Tamara Maes is exiting the board of Oryzon Genomics, having contributed to the company’s mission of advancing psychiatric treatments during her tenure.
Power0
Reach0
Collect
Not in the pool (under ¢1).
Recent news mentions
Tamara Maes is set to leave the Oryzon board.
Oryzon duplica su valor en Bolsa desde enero con sus últimos avances en tratamientos en psiquiatría | EmpresasEl País·
Spain· 2025-02-24
Spain· 2025-02-24
